Patients With Leukemia Have Higher Infection Risk During Immunoglobulin Replacement Therapy

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 7, 2025.

via HealthDay

THURSDAY, Aug. 7, 2025 -- For patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy (IgRT) is associated with an increased incidence of infections, according to a study published online July 30 in Blood Advances.

Sara Carrillo De Albornoz, M.P.H., from Monash University in Melbourne, Australia, and colleagues described IgRT treatment patterns in a large, real-world cohort of patients with CLL and explored the association between IgRT and serious infections in a retrospective longitudinal study of linked hospital data. A total of 6,217 patients with CLL between 2008 and 2022 were included in the study.

The researchers found that the monthly proportion of patients experiencing serious infections doubled and the proportion of patients receiving any IgRT quadrupled during the 14-year follow-up. The median time from CLL diagnosis to death was 10 years; a higher mortality rate was seen for patients with versus those without serious infections (0.090 versus 0.008). Overall, 12.1 and 8.4 percent of patients received IgRT and received IgRT regularly, respectively. Compared with periods without IgRT, infection incidence was higher during periods of IgRT among patients who received IgRT regularly (0.056 versus 0.038). Serious infections were associated with IgRT initiation, reinitiation, and cessation.

"The cost of this therapy, its burden to patients, and the patterns of use and infection we observed are a clear call for better guidelines on the use of immunoglobulins," Carrillo De Albornoz said in a statement. "Although there are criteria for access to government-funded therapy in this population in Australia, clear clinical guidelines are lacking."

Two authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-08 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords